Alembic Pharmaceuticals’s joint venture Aleor Dermaceuticals receives US FDA final approval for Mupirocin Cream USP, 2%

Alembic Pharmaceuticals yesterday announced that its joint venture Aleor Dermaceuticals (Aleor) has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Mupirocin Cream USP, 2%. The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Bactroban Cream, 2% of SmithKline Beecham (Cork), Ireland (SmithKline), the company said in a statement.

Mupirocin Cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length) due to susceptible strains of S aureus and S pyogenes. Aleor has been granted a Competitive Generic Therapies (CGT) designation for this ANDA and it is eligible for 180 days of CGT exclusivity as it is the first approved applicant.

Mupirocin Cream USP, 2% has an estimated market size of $28 million for twelve months ending June 2021, according to IQVIAl, added the statement.

Alembic has received year to date (YTD) 13 approvals (10 final approvals and three tentative approvals) and a cumulative total of 152 ANDA approvals (133 final approvals and 19 tentative approvals) from FDA.